Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010 (2010), Article ID 841343, 12 pages
http://dx.doi.org/10.1155/2010/841343
Research Article

The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat

1Division of Endocrinology and Metabolism, Department of Medicine, Georgetown University, Washington, DC 20057, USA
2Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA

Received 2 October 2009; Revised 27 January 2010; Accepted 5 March 2010

Academic Editor: Giuseppe Matarese

Copyright © 2010 Carolyn M. Ecelbarger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. R. Tuttle, J. H. Stein, and R. A. DeFronzo, “The natural history of diabetic nephropathy,” Seminars in Nephrology, vol. 10, no. 3, pp. 184–193, 1990. View at Google Scholar · View at Scopus
  2. “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group,” Lancet, vol. 352, pp. 837–853, 1998.
  3. “Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study,” The Journal of the American Medical Association, vol. 290, pp. 2159–2167, 2003.
  4. “Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group,” British Medical Journal, vol. 317, pp. 703–713, 1998.
  5. C. Mora and J. F. Navarro, “Inflammation and diabetic nephropathy,” Current Diabetes Reports, vol. 6, pp. 463–468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. F. Navarro and C. Mora, “Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy,” The Scientific World Journal, vol. 6, pp. 908–917, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. F. Navarro and C. Mora, “Role of inflammation in diabetic complications,” Nephrology Dialysis Transplantation, vol. 20, no. 12, pp. 2601–2604, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. E. Raptis and G. Viberti, “Pathogenesis of diabetic nephropathy,” Experimental and Clinical Endocrinology and Diabetes, vol. 109, supplement 2, pp. S424–S437, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. K. R. Tuttle, “Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease,” Journal of the American Society of Nephrology, vol. 16, no. 6, pp. 1537–1538, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. S. D. Crowley, S. B. Gurley, M. J. Herrera et al., “Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 47, pp. 17985–17990, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Giacchetti, L. A. Sechi, S. Rilli, and R. M. Carey, “The renin-angiotensin-aldosterone system, glucose metabolism and diabetes,” Trends in Endocrinology and Metabolism, vol. 16, no. 3, pp. 120–126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Hussain, “Renal angiotensin II receptors, hyperinsulinemia, and obesity,” Clinical and Experimental Hypertension, vol. 25, no. 7, pp. 395–403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Kopp, “Pathogenesis and etiology of essential hypertension: role of dietary carbohydrate,” Medical Hypotheses, vol. 64, pp. 782–787, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. R. H. Rao, “Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats,” American Journal of Hypertension, vol. 7, no. 7, pp. 655–660, 1994. View at Google Scholar · View at Scopus
  15. R. H. Rao, “Pressor doses of angiotensin II increase hepatic glucose output and decrease insulin sensitivity in rats,” Journal of Endocrinology, vol. 148, no. 2, pp. 311–318, 1996. View at Google Scholar · View at Scopus
  16. R. Dechend, A. Fiebler, C. Lindschau et al., “Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition,” American Journal of Hypertension, vol. 14, no. 6, pp. 55S–61S, 2001. View at Google Scholar · View at Scopus
  17. M. Ruiz-Ortega, M. Rupérez, V. Esteban et al., “Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases,” Nephrology Dialysis Transplantation, vol. 21, no. 1, pp. 16–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. B. M. Brenner, M. E. Cooper, D. D. Zeeuw et al., “The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan),” Journal of Renin-Angiotensin-Aldosterone System, vol. 1, pp. 328–335, 2000. View at Google Scholar
  19. R. M. Carey and H. M. Siragy, “The intrarenal renin-angiotensin system and diabetic nephropathy,” Trends in Endocrinology and Metabolism, vol. 14, no. 6, pp. 274–281, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. N. K. Hollenberg, D. A. Price, N. D. L. Fisher et al., “Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus,” Kidney International, vol. 63, no. 1, pp. 172–178, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Noda, T. Matsuo, H. Nagano-Tsuge et al., “Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats),” Japanese Journal of Pharmacology, vol. 85, no. 4, pp. 416–422, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Iida, T. Murakami, K. Ishida, A. Mizuno, M. Kuwajima, and K. Shima, “Phenotype-linked amino acid alteration in leptin receptor cDNA from Zucker fatty (fa/fa) rat,” Biochemical and Biophysical Research Communications, vol. 222, no. 1, pp. 19–26, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. B. L. Kasiske, M. P. O'Donnell, and W. F. Keane, “The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury,” Hypertension, vol. 19, pp. I110–I115, 1992. View at Google Scholar
  24. V. K. Madala Halagappa, S. Tiwari, S. Riazi, X. Hu, and C. M. Ecelbarger, “Chronic candesartan alters expression and activity of NKCC2, NCC, and ENaC in the obese Zucker rat,” American Journal of Physiology, vol. 294, pp. F1222–F1231, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Benicky, E. Sánchez-Lemus, J. Pavel, and J. M. Saavedra, “Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery,” Cellular and Molecular Neurobiology, vol. 29, no. 6-7, pp. 781–792, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Kohno, T. Anzai, K. Naito et al., “Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling,” Circulation Journal, vol. 72, no. 10, pp. 1685–1692, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Sanchez-Lemus, Y. Murakami, I. M. Larrayoz-Roldan et al., “Angiotensin II at1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland,” Endocrinology, vol. 149, no. 10, pp. 5177–5188, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. R. A. Benndorf, T. Rudolph, D. Appel et al., “Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension,” Metabolism, vol. 55, no. 9, pp. 1159–1164, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. E. J. Henriksen, S. Jacob, T. R. Kinnick, M. K. Teachey, and M. Krekler, “Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats,” Hypertension, vol. 38, no. 4, pp. 884–890, 2001. View at Google Scholar · View at Scopus
  30. T. Shiuchi, M. Iwai, H.-S. Li et al., “Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice,” Hypertension, vol. 43, no. 5, pp. 1003–1010, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Yamagishi, K. Nakamura, and T. Matsui, “Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders,” Current Molecular Medicine, vol. 7, pp. 463–469, 2007. View at Google Scholar
  32. O. Khan, S. Riazi, X. Hu, J. Song, J. B. Wade, and C. A. Ecelbarger, “Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone,” American Journal of Physiology, vol. 289, pp. F442–F450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Riazi, S. Tiwari, N. Sharma, A. Rash, and C. M. Ecelbarger, “Abundance of the Na-K-2Cl cotransporter NKCC2 is increased by high-fat feeding in Fischer 344 X Brown Norway (F1) rats,” American Journal of Physiology, vol. 296, pp. F762–F770, 2009. View at Google Scholar
  34. J. Song, X. Hu, S. Riazi, S. Tiwari, J. B. Wade, and C. A. Ecelbarger, “Regulation of blood pressure, the epithelial sodium channel (ENaC), and other key renal sodium transporters by chronic insulin infusion in rats,” American Journal of Physiology, vol. 290, pp. F1055–F1064, 2006. View at Google Scholar
  35. S. Tiwari, V. K. Halagappa, S. Riazi, X. Hu, and C. A. Ecelbarger, “Reduced expression of insulin receptors in the kidneys of insulin-resistant rats,” Journal of the American Society of Nephrology, vol. 18, no. 10, pp. 2661–2671, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. C. A. Bickel, M. A. Knepper, J. G. Verbalis, and C. A. Ecelbarger, “Dysregulation of renal salt and water transport proteins in diabetic Zucker rats,” Kidney International, vol. 61, no. 6, pp. 2099–2110, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Van Goor, V. Fidler, J. J. Weening, and J. Grond, “Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation: evidence for involvement of macrophages and lipids,” Laboratory Investigation, vol. 64, no. 6, pp. 754–765, 1991. View at Google Scholar · View at Scopus
  38. C. S. Wilcox, “Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension?” American Journal of Physiology, vol. 289, no. 4, pp. R913–R935, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. F. N. Ziyadeh, “Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 82, supplement 1, pp. S38–S41, 2008. View at Google Scholar
  40. G. Chandramohan, Y. Bai, K. Norris, B. Rodriguez-Iturbe, and N. D. Vaziri, “Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-κB activity in salt-sensitive and -resistant rat kidneys,” American Journal of Nephrology, vol. 28, no. 1, pp. 158–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. F. Navarro, F. J. Milena, C. Mora, C. Leon, and J. García, “Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration,” American Journal of Nephrology, vol. 26, pp. 562–570, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. Z.-G. Xu, L. Lanting, N. D. Vaziri et al., “Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade,” Circulation, vol. 111, no. 15, pp. 1962–1969, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Waldherr, I. L. Noronha, Z. Niemir, C. Kruger, H. Stein, and G. Stumm, “Expression of cytokines and growth factors in human glomerulonephritides,” Pediatric Nephrology, vol. 7, no. 4, pp. 471–478, 1993. View at Google Scholar · View at Scopus
  44. D. Suzuki, M. Miyazaki, R. Naka et al., “In situ hybridization of interleukin 6 in diabetic nephropathy,” Diabetes, vol. 44, no. 10, pp. 1233–1238, 1995. View at Google Scholar · View at Scopus
  45. Y. Quan, J. Du, and X. Wang, “High glucose stimulates GRO secretion from rat microglia via ROS 5 PKC, and NF-κB pathways,” Journal of Neuroscience Research, vol. 85, no. 14, pp. 3150–3159, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. H. Bani-Hani, J. A. Leslie, H. Asanuma et al., “IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis,” Kidney International, vol. 76, no. 5, pp. 500–511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. M. G. Netea, L. A. B. Joosten, E. Lewis et al., “Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance,” Nature Medicine, vol. 12, no. 6, pp. 650–656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. Y.-S. Yang, X.-Y. Li, J. Hong et al., “Interleukin-18 enhances glucose uptake in 3T3-L1 adipocytes,” Endocrine, vol. 32, no. 3, pp. 297–302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. Y.-F. Zhang, Y.-S. Yang, J. Hong et al., “Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome,” Endocrine, vol. 29, no. 3, pp. 419–423, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. G. R. C. Zilverschoon, C. J. Tack, L. A. B. Joosten, B. J. Kullberg, J. W. M. Van Der Meer, and M. G. Netea, “Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus,” International Journal of Obesity, vol. 32, no. 9, pp. 1407–1414, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Barra, A. Vitagliano, V. Cuomo, G. Vitagliano, and G. Gaeta, “Vascular and metabolic effects of angiotensin II receptor blockers,” Expert Opinion on Pharmacotherapy, vol. 10, no. 2, pp. 173–189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. M. E. Cooper, C. Tikellis, and M. C. Thomas, “Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system,” Journal of Hypertension Supplement, vol. 24, no. 1, pp. S57–S63, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Tikellis, P. J. Wookey, R. Candido, S. Andrikopoulos, M. C. Thomas, and M. E. Cooper, “Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat,” Diabetes, vol. 53, no. 4, pp. 989–997, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. W.-H. Yan, J.-T. Dou, C.-Y. Pan et al., “Candesartan improves insulin resistance induced by high-fat diet in rats,” Zhonghua Yi Xue Za Zhi, vol. 88, no. 38, pp. 2695–2699, 2008. View at Google Scholar · View at Scopus
  55. M. Clodi, M. Resl, D. Stelzeneder et al., “Interactions of glucose metabolism and chronic heart failure,” Experimental and Clinical Endocrinology and Diabetes, vol. 117, no. 3, pp. 99–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Trenkwalder, “Effects of candesartan cilexetil on glucose homeostasis. Multicenter Study Group,” Basic Research in Cardiology, vol. 93, supplement 2, pp. 140–144, 1998. View at Google Scholar
  57. P. Trenkwalder, “Efficacy and tolerability of candesartan cilexetil in special patient groups,” Blood Pressure, vol. 9, supplement 1, pp. 27–30, 2000. View at Google Scholar · View at Scopus
  58. P. Trenkwalder, M. Lehtovirta, and K. Dahl, “Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes,” Journal of Human Hypertension, vol. 11, supplement 2, pp. S81–S83, 1997. View at Google Scholar · View at Scopus
  59. A. Seltzer, C. Bregonzio, I. Armando, G. Baiardi, and J. M. Saavedra, “Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats,” Brain Research, vol. 1028, no. 1, pp. 9–18, 2004. View at Publisher · View at Google Scholar · View at Scopus